Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 197 entries
Sorted by: Best Match Show Resources per page
The Bone Morphogenetic Protein Pathway: The Osteoclastic Perspective.

Frontiers in cell and developmental biology

Lademann F, Hofbauer LC, Rauner M.
PMID: 33178699
Front Cell Dev Biol. 2020 Oct 16;8:586031. doi: 10.3389/fcell.2020.586031. eCollection 2020.

Bone health crucially relies on constant bone remodeling and bone regeneration, both tightly controlled processes requiring bone formation and bone resorption. Plenty of evidence identifies bone morphogenetic proteins (BMP) as major players in osteoblast differentiation and thus, bone formation....

Cite
Lademann F, Hofbauer LC, Rauner M. The Bone Morphogenetic Protein Pathway: The Osteoclastic Perspective. Front Cell Dev Biol. 2020;8:586031doi: 10.3389/fcell.2020.586031.
Lademann, F., Hofbauer, L. C., & Rauner, M. (2020). The Bone Morphogenetic Protein Pathway: The Osteoclastic Perspective. Frontiers in cell and developmental biology, 8586031. https://doi.org/10.3389/fcell.2020.586031
Lademann, Franziska, et al. "The Bone Morphogenetic Protein Pathway: The Osteoclastic Perspective." Frontiers in cell and developmental biology vol. 8 (2020): 586031. doi: https://doi.org/10.3389/fcell.2020.586031
Lademann F, Hofbauer LC, Rauner M. The Bone Morphogenetic Protein Pathway: The Osteoclastic Perspective. Front Cell Dev Biol. 2020 Oct 16;8:586031. doi: 10.3389/fcell.2020.586031. eCollection 2020. PMID: 33178699; PMCID: PMC7597383.
Copy Download .nbib Format: NLM
Neutrophil Extracellular Traps Induce MCP-1 at the Culprit Site in ST-Segment Elevation Myocardial Infarction.

Frontiers in cell and developmental biology

Hofbauer TM, Ondracek AS, Mangold A, Scherz T, Nechvile J, Seidl V, Brostjan C, Lang IM.
PMID: 33240874
Front Cell Dev Biol. 2020 Nov 09;8:564169. doi: 10.3389/fcell.2020.564169. eCollection 2020.

BACKGROUND: Leukocyte-mediated inflammation is crucial in ST-segment elevation myocardial infarction (STEMI). We recently observed that neutrophil extracellular traps (NETs) are increased at the culprit site, promoting activation and differentiation of fibrocytes, cells with mesenchymal and leukocytic properties. Fibrocyte migration...

Cite
Hofbauer TM, Ondracek AS, Mangold A, et al. Neutrophil Extracellular Traps Induce MCP-1 at the Culprit Site in ST-Segment Elevation Myocardial Infarction. Front Cell Dev Biol. 2020;8:564169doi: 10.3389/fcell.2020.564169.
Hofbauer, T. M., Ondracek, A. S., Mangold, A., Scherz, T., Nechvile, J., Seidl, V., Brostjan, C., & Lang, I. M. (2020). Neutrophil Extracellular Traps Induce MCP-1 at the Culprit Site in ST-Segment Elevation Myocardial Infarction. Frontiers in cell and developmental biology, 8564169. https://doi.org/10.3389/fcell.2020.564169
Hofbauer, Thomas M, et al. "Neutrophil Extracellular Traps Induce MCP-1 at the Culprit Site in ST-Segment Elevation Myocardial Infarction." Frontiers in cell and developmental biology vol. 8 (2020): 564169. doi: https://doi.org/10.3389/fcell.2020.564169
Hofbauer TM, Ondracek AS, Mangold A, Scherz T, Nechvile J, Seidl V, Brostjan C, Lang IM. Neutrophil Extracellular Traps Induce MCP-1 at the Culprit Site in ST-Segment Elevation Myocardial Infarction. Front Cell Dev Biol. 2020 Nov 09;8:564169. doi: 10.3389/fcell.2020.564169. eCollection 2020. PMID: 33240874; PMCID: PMC7680894.
Copy Download .nbib Format: NLM
Rapid growth of new atmospheric particles by nitric acid and ammonia condensation.

Nature

Wang M, Kong W, Marten R, He XC, Chen D, Pfeifer J, Heitto A, Kontkanen J, Dada L, Kürten A, Yli-Juuti T, Manninen HE, Amanatidis S, Amorim A, Baalbaki R, Baccarini A, Bell DM, Bertozzi B, Bräkling S, Brilke S, Murillo LC, Chiu R, Chu B, De Menezes LP, Duplissy J, Finkenzeller H, Carracedo LG, Granzin M, Guida R, Hansel A, Hofbauer V, Krechmer J, Lehtipalo K, Lamkaddam H, Lampimäki M, Lee CP, Makhmutov V, Marie G, Mathot S, Mauldin RL, Mentler B, Müller T, Onnela A, Partoll E, Petäjä T, Philippov M, Pospisilova V, Ranjithkumar A, Rissanen M, Rörup B, Scholz W, Shen J, Simon M, Sipilä M, Steiner G, Stolzenburg D, Tham YJ, Tomé A, Wagner AC, Wang DS, Wang Y, Weber SK, Winkler PM, Wlasits PJ, Wu Y, Xiao M, Ye Q, Zauner-Wieczorek M, Zhou X, Volkamer R, Riipinen I, Dommen J, Curtius J, Baltensperger U, Kulmala M, Worsnop DR, Kirkby J, Seinfeld JH, El-Haddad I, Flagan RC, Donahue NM.
PMID: 32405020
Nature. 2020 May;581(7807):184-189. doi: 10.1038/s41586-020-2270-4. Epub 2020 May 13.

A list of authors and their affiliations appears at the end of the paper New-particle formation is a major contributor to urban smog

Cite
Wang M, Kong W, Marten R, et al. Rapid growth of new atmospheric particles by nitric acid and ammonia condensation. Nature. 2020;581(7807):184-189doi: 10.1038/s41586-020-2270-4.
Wang, M., Kong, W., Marten, R., He, X. C., Chen, D., Pfeifer, J., Heitto, A., Kontkanen, J., Dada, L., Kürten, A., Yli-Juuti, T., Manninen, H. E., Amanatidis, S., Amorim, A., Baalbaki, R., Baccarini, A., Bell, D. M., Bertozzi, B., Bräkling, S., Brilke, S., Murillo, L. C., Chiu, R., Chu, B., De Menezes, L. P., Duplissy, J., Finkenzeller, H., Carracedo, L. G., Granzin, M., Guida, R., Hansel, A., Hofbauer, V., Krechmer, J., Lehtipalo, K., Lamkaddam, H., Lampimäki, M., Lee, C. P., Makhmutov, V., Marie, G., Mathot, S., Mauldin, R. L., Mentler, B., Müller, T., Onnela, A., Partoll, E., Petäjä, T., Philippov, M., Pospisilova, V., Ranjithkumar, A., Rissanen, M., Rörup, B., Scholz, W., Shen, J., Simon, M., Sipilä, M., Steiner, G., Stolzenburg, D., Tham, Y. J., Tomé, A., Wagner, A. C., Wang, D. S., Wang, Y., Weber, S. K., Winkler, P. M., Wlasits, P. J., Wu, Y., Xiao, M., Ye, Q., Zauner-Wieczorek, M., Zhou, X., Volkamer, R., Riipinen, I., Dommen, J., Curtius, J., Baltensperger, U., Kulmala, M., Worsnop, D. R., Kirkby, J., Seinfeld, J. H., El-Haddad, I., Flagan, R. C., & Donahue, N. M. (2020). Rapid growth of new atmospheric particles by nitric acid and ammonia condensation. Nature, 581(7807), 184-189. https://doi.org/10.1038/s41586-020-2270-4
Wang, Mingyi, et al. "Rapid growth of new atmospheric particles by nitric acid and ammonia condensation." Nature vol. 581,7807 (2020): 184-189. doi: https://doi.org/10.1038/s41586-020-2270-4
Wang M, Kong W, Marten R, He XC, Chen D, Pfeifer J, Heitto A, Kontkanen J, Dada L, Kürten A, Yli-Juuti T, Manninen HE, Amanatidis S, Amorim A, Baalbaki R, Baccarini A, Bell DM, Bertozzi B, Bräkling S, Brilke S, Murillo LC, Chiu R, Chu B, De Menezes LP, Duplissy J, Finkenzeller H, Carracedo LG, Granzin M, Guida R, Hansel A, Hofbauer V, Krechmer J, Lehtipalo K, Lamkaddam H, Lampimäki M, Lee CP, Makhmutov V, Marie G, Mathot S, Mauldin RL, Mentler B, Müller T, Onnela A, Partoll E, Petäjä T, Philippov M, Pospisilova V, Ranjithkumar A, Rissanen M, Rörup B, Scholz W, Shen J, Simon M, Sipilä M, Steiner G, Stolzenburg D, Tham YJ, Tomé A, Wagner AC, Wang DS, Wang Y, Weber SK, Winkler PM, Wlasits PJ, Wu Y, Xiao M, Ye Q, Zauner-Wieczorek M, Zhou X, Volkamer R, Riipinen I, Dommen J, Curtius J, Baltensperger U, Kulmala M, Worsnop DR, Kirkby J, Seinfeld JH, El-Haddad I, Flagan RC, Donahue NM. Rapid growth of new atmospheric particles by nitric acid and ammonia condensation. Nature. 2020 May;581(7807):184-189. doi: 10.1038/s41586-020-2270-4. Epub 2020 May 13. PMID: 32405020; PMCID: PMC7334196.
Copy Download .nbib Format: NLM
The Thyroid Hormone Transporter MCT10 Is a Novel Regulator of Trabecular Bone Mass and Bone Turnover in Male Mice.

Endocrinology

Lademann F, Mayerl S, Tsourdi E, Verrey F, Leitch VD, Williams GR, Bassett JHD, Hofbauer LC, Heuer H, Rauner M.
PMID: 34669927
Endocrinology. 2022 Jan 01;163(1). doi: 10.1210/endocr/bqab218.

Thyroid hormones (TH) are essential for skeletal development and adult bone homeostasis. Their bioavailability is determined by specific transporter proteins at the cell surface. The TH-specific transporter monocarboxylate transporter 8 (MCT8) was recently reported as a regulator of bone...

Cite
Lademann F, Mayerl S, Tsourdi E, et al. The Thyroid Hormone Transporter MCT10 Is a Novel Regulator of Trabecular Bone Mass and Bone Turnover in Male Mice. Endocrinology. 2022;163(1)doi: 10.1210/endocr/bqab218.
Lademann, F., Mayerl, S., Tsourdi, E., Verrey, F., Leitch, V. D., Williams, G. R., Bassett, J. H. D., Hofbauer, L. C., Heuer, H., & Rauner, M. (2022). The Thyroid Hormone Transporter MCT10 Is a Novel Regulator of Trabecular Bone Mass and Bone Turnover in Male Mice. Endocrinology, 163(1), . https://doi.org/10.1210/endocr/bqab218
Lademann, Franziska, et al. "The Thyroid Hormone Transporter MCT10 Is a Novel Regulator of Trabecular Bone Mass and Bone Turnover in Male Mice." Endocrinology vol. 163,1 (2022). doi: https://doi.org/10.1210/endocr/bqab218
Lademann F, Mayerl S, Tsourdi E, Verrey F, Leitch VD, Williams GR, Bassett JHD, Hofbauer LC, Heuer H, Rauner M. The Thyroid Hormone Transporter MCT10 Is a Novel Regulator of Trabecular Bone Mass and Bone Turnover in Male Mice. Endocrinology. 2022 Jan 01;163(1). doi: 10.1210/endocr/bqab218. PMID: 34669927; PMCID: PMC8598386.
Copy Download .nbib Format: NLM
Impact of the dynamics of the catalytic arginine on nitrite and chlorite binding by dimeric chlorite dismutase.

Journal of inorganic biochemistry

Serra I, Schmidt D, Pfanzagl V, Mlynek G, Hofbauer S, Djinović-Carugo K, Furtmüller PG, García-Rubio I, Van Doorslaer S, Obinger C.
PMID: 34922158
J Inorg Biochem. 2021 Dec 10;227:111689. doi: 10.1016/j.jinorgbio.2021.111689. Epub 2021 Dec 10.

Chlorite dismutases (Clds) are heme b containing oxidoreductases able to decompose chlorite to chloride and molecular oxygen. This work analyses the impact of the distal, flexible and catalytic arginine on the binding of anionic angulate ligands like nitrite and...

Cite
Serra I, Schmidt D, Pfanzagl V, et al. Impact of the dynamics of the catalytic arginine on nitrite and chlorite binding by dimeric chlorite dismutase. J Inorg Biochem. 2021;227:111689doi: 10.1016/j.jinorgbio.2021.111689.
Serra, I., Schmidt, D., Pfanzagl, V., Mlynek, G., Hofbauer, S., Djinović-Carugo, K., Furtmüller, P. G., García-Rubio, I., Van Doorslaer, S., & Obinger, C. (2021). Impact of the dynamics of the catalytic arginine on nitrite and chlorite binding by dimeric chlorite dismutase. Journal of inorganic biochemistry, 227111689. https://doi.org/10.1016/j.jinorgbio.2021.111689
Serra, Ilenia, et al. "Impact of the dynamics of the catalytic arginine on nitrite and chlorite binding by dimeric chlorite dismutase." Journal of inorganic biochemistry vol. 227 (2021): 111689. doi: https://doi.org/10.1016/j.jinorgbio.2021.111689
Serra I, Schmidt D, Pfanzagl V, Mlynek G, Hofbauer S, Djinović-Carugo K, Furtmüller PG, García-Rubio I, Van Doorslaer S, Obinger C. Impact of the dynamics of the catalytic arginine on nitrite and chlorite binding by dimeric chlorite dismutase. J Inorg Biochem. 2021 Dec 10;227:111689. doi: 10.1016/j.jinorgbio.2021.111689. Epub 2021 Dec 10. PMID: 34922158.
Copy Download .nbib Format: NLM
Binaural Signal Processing in Hearing Aids.

Seminars in hearing

Derleth P, Georganti E, Latzel M, Courtois G, Hofbauer M, Raether J, Kuehnel V.
PMID: 34594085
Semin Hear. 2021 Aug;42(3):206-223. doi: 10.1055/s-0041-1735176. Epub 2021 Sep 24.

For many years, clinicians have understood the advantages of listening with two ears compared with one. In addition to improved speech intelligibility in quiet, noisy, and reverberant environments, binaural versus monaural listening improves perceived sound quality and decreases the...

Cite
Derleth P, Georganti E, Latzel M, et al. Binaural Signal Processing in Hearing Aids. Semin Hear. 2021;42(3):206-223doi: 10.1055/s-0041-1735176.
Derleth, P., Georganti, E., Latzel, M., Courtois, G., Hofbauer, M., Raether, J., & Kuehnel, V. (2021). Binaural Signal Processing in Hearing Aids. Seminars in hearing, 42(3), 206-223. https://doi.org/10.1055/s-0041-1735176
Derleth, Peter, et al. "Binaural Signal Processing in Hearing Aids." Seminars in hearing vol. 42,3 (2021): 206-223. doi: https://doi.org/10.1055/s-0041-1735176
Derleth P, Georganti E, Latzel M, Courtois G, Hofbauer M, Raether J, Kuehnel V. Binaural Signal Processing in Hearing Aids. Semin Hear. 2021 Aug;42(3):206-223. doi: 10.1055/s-0041-1735176. Epub 2021 Sep 24. PMID: 34594085; PMCID: PMC8463127.
Copy Download .nbib Format: NLM
Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS.

The Journal of clinical endocrinology and metabolism

Tsourdi E, Zillikens MC, Meier C, Body JJ, Gonzalez Rodriguez E, Anastasilakis AD, Abrahamsen B, McCloskey E, Hofbauer LC, Guañabens N, Obermayer-Pietsch B, Ralston SH, Eastell R, Pepe J, Palermo A, Langdahl B.
PMID: 33103722
J Clin Endocrinol Metab. 2020 Oct 26; doi: 10.1210/clinem/dgaa756. Epub 2020 Oct 26.

CONTEXT: Denosumab discontinuation is characterized by an increase in bone turnover overriding pre-treatment status, a rapid bone loss in the majority and multiple vertebral fractures (VFx) in some patients.METHODS: A working group of the European Calcified Tissue Society (ECTS)...

Cite
Tsourdi E, Zillikens MC, Meier C, et al. Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS. J Clin Endocrinol Metab. 2020;doi: 10.1210/clinem/dgaa756.
Tsourdi, E., Zillikens, M. C., Meier, C., Body, J. J., Gonzalez Rodriguez, E., Anastasilakis, A. D., Abrahamsen, B., McCloskey, E., Hofbauer, L. C., Guañabens, N., Obermayer-Pietsch, B., Ralston, S. H., Eastell, R., Pepe, J., Palermo, A., & Langdahl, B. (2020). Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS. The Journal of clinical endocrinology and metabolism, . https://doi.org/10.1210/clinem/dgaa756
Tsourdi, Elena, et al. "Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS." The Journal of clinical endocrinology and metabolism vol. (2020). doi: https://doi.org/10.1210/clinem/dgaa756
Tsourdi E, Zillikens MC, Meier C, Body JJ, Gonzalez Rodriguez E, Anastasilakis AD, Abrahamsen B, McCloskey E, Hofbauer LC, Guañabens N, Obermayer-Pietsch B, Ralston SH, Eastell R, Pepe J, Palermo A, Langdahl B. Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS. J Clin Endocrinol Metab. 2020 Oct 26; doi: 10.1210/clinem/dgaa756. Epub 2020 Oct 26. PMID: 33103722.
Copy Download .nbib Format: NLM
18F-Fluoride PET/MR for painful lumbar facet joint degeneration - a randomized controlled clinical trial.

The spine journal : official journal of the North American Spine Society

Spirig JM, Hüllner M, Cornaz F, Betz M, Wanivenhaus F, Hofbauer M, Johayem A, Kaufmann PA, Farshad M.
PMID: 34848344
Spine J. 2021 Nov 27; doi: 10.1016/j.spinee.2021.11.014. Epub 2021 Nov 27.

BACKGROUND CONTEXT: [18F]-sodium fluoride (NaF) PET/MR is a modern diagnostic modality for imaging increased bone turnover. Its merits in detecting painful facet joint osteoarthritis in patients with lumbar back pain are unknown.PURPOSE: To perform a prospective randomized controlled study...

Cite
Spirig JM, Hüllner M, Cornaz F, et al. 18F-Fluoride PET/MR for painful lumbar facet joint degeneration - a randomized controlled clinical trial. Spine J. 2021;doi: 10.1016/j.spinee.2021.11.014.
Spirig, J. M., Hüllner, M., Cornaz, F., Betz, M., Wanivenhaus, F., Hofbauer, M., Johayem, A., Kaufmann, P. A., & Farshad, M. (2021). 18F-Fluoride PET/MR for painful lumbar facet joint degeneration - a randomized controlled clinical trial. The spine journal : official journal of the North American Spine Society, . https://doi.org/10.1016/j.spinee.2021.11.014
Spirig, José Miguel, et al. "18F-Fluoride PET/MR for painful lumbar facet joint degeneration - a randomized controlled clinical trial." The spine journal : official journal of the North American Spine Society vol. (2021). doi: https://doi.org/10.1016/j.spinee.2021.11.014
Spirig JM, Hüllner M, Cornaz F, Betz M, Wanivenhaus F, Hofbauer M, Johayem A, Kaufmann PA, Farshad M. 18F-Fluoride PET/MR for painful lumbar facet joint degeneration - a randomized controlled clinical trial. Spine J. 2021 Nov 27; doi: 10.1016/j.spinee.2021.11.014. Epub 2021 Nov 27. PMID: 34848344.
Copy Download .nbib Format: NLM
Stereospecific Response of E/Z-isomers of N-Nitrososarcosine in LC-ESI-MS/MS.

Journal of chromatographic science

Werneth M, Pani J, Hofbauer L, Pummer S, Weber MT, Pour G, Kählig H, Mayer-Helm B, Stepan H.
PMID: 33618358
J Chromatogr Sci. 2021 Sep 29;59(9):813-822. doi: 10.1093/chromsci/bmab013.

The carcinogenic compound N-nitrososarcosine (NSAR) is found in foods and tobacco products, and its quantification is of great interest. Although the presence of two stereoisomers, E- and Z-NSAR, is well-known, individual investigation of the isomers has not been reported...

Cite
Werneth M, Pani J, Hofbauer L, et al. Stereospecific Response of E/Z-isomers of N-Nitrososarcosine in LC-ESI-MS/MS. J Chromatogr Sci. 2021;59(9):813-822doi: 10.1093/chromsci/bmab013.
Werneth, M., Pani, J., Hofbauer, L., Pummer, S., Weber, M. T., Pour, G., Kählig, H., Mayer-Helm, B., & Stepan, H. (2021). Stereospecific Response of E/Z-isomers of N-Nitrososarcosine in LC-ESI-MS/MS. Journal of chromatographic science, 59(9), 813-822. https://doi.org/10.1093/chromsci/bmab013
Werneth, Madeleine, et al. "Stereospecific Response of E/Z-isomers of N-Nitrososarcosine in LC-ESI-MS/MS." Journal of chromatographic science vol. 59,9 (2021): 813-822. doi: https://doi.org/10.1093/chromsci/bmab013
Werneth M, Pani J, Hofbauer L, Pummer S, Weber MT, Pour G, Kählig H, Mayer-Helm B, Stepan H. Stereospecific Response of E/Z-isomers of N-Nitrososarcosine in LC-ESI-MS/MS. J Chromatogr Sci. 2021 Sep 29;59(9):813-822. doi: 10.1093/chromsci/bmab013. PMID: 33618358.
Copy Download .nbib Format: NLM
A non-inferiority comparative analysis of micro-ultrasonography and MRI-targeted biopsy in men at risk of prostate cancer.

BJU international

Hofbauer SL, Luger F, Harland N, Plage H, Reimann M, Hollenbach M, Gusenleitner A, Stenzl A, Schlomm T, Wiemer L, Cash H.
PMID: 34773679
BJU Int. 2021 Nov 13; doi: 10.1111/bju.15635. Epub 2021 Nov 13.

OBJECTIVE: To compare the efficacy of multiparametric magnetic resonance imaging (mpMRI)-directed and micro-ultrasonography (micro-US)-directed biopsy for detecting clinically significant (Grade Group >1) prostate cancer (csPCa).MATERIALS AND METHODS: A total of 203 patients were prospectively enrolled at three institutions across...

Cite
Hofbauer SL, Luger F, Harland N, et al. A non-inferiority comparative analysis of micro-ultrasonography and MRI-targeted biopsy in men at risk of prostate cancer. BJU Int. 2021;doi: 10.1111/bju.15635.
Hofbauer, S. L., Luger, F., Harland, N., Plage, H., Reimann, M., Hollenbach, M., Gusenleitner, A., Stenzl, A., Schlomm, T., Wiemer, L., & Cash, H. (2021). A non-inferiority comparative analysis of micro-ultrasonography and MRI-targeted biopsy in men at risk of prostate cancer. BJU international, . https://doi.org/10.1111/bju.15635
Hofbauer, Sebastian L, et al. "A non-inferiority comparative analysis of micro-ultrasonography and MRI-targeted biopsy in men at risk of prostate cancer." BJU international vol. (2021). doi: https://doi.org/10.1111/bju.15635
Hofbauer SL, Luger F, Harland N, Plage H, Reimann M, Hollenbach M, Gusenleitner A, Stenzl A, Schlomm T, Wiemer L, Cash H. A non-inferiority comparative analysis of micro-ultrasonography and MRI-targeted biopsy in men at risk of prostate cancer. BJU Int. 2021 Nov 13; doi: 10.1111/bju.15635. Epub 2021 Nov 13. PMID: 34773679.
Copy Download .nbib Format: NLM
The PARADIGHM (physicians advancing disease knowledge in hypoparathyroidism) registry for patients with chronic hypoparathyroidism: study protocol and interim baseline patient characteristics.

BMC endocrine disorders

Gittoes N, Rejnmark L, Ing SW, Brandi ML, Björnsdottir S, Hahner S, Hofbauer LC, Houillier P, Khan AA, Levine MA, Mannstadt M, Shoback DM, Vokes TJ, Zhang P, Marelli C, Germak J, Clarke BL.
PMID: 34801015
BMC Endocr Disord. 2021 Nov 20;21(1):232. doi: 10.1186/s12902-021-00888-2.

BACKGROUND: The PARADIGHM registry of adult and pediatric patients with chronic hypoparathyroidism evaluates the long-term safety and effectiveness of treatment with recombinant human parathyroid hormone, rhPTH(1-84), and describes the clinical disease course under conditions of routine clinical practice. In...

Cite
Gittoes N, Rejnmark L, Ing SW, et al. The PARADIGHM (physicians advancing disease knowledge in hypoparathyroidism) registry for patients with chronic hypoparathyroidism: study protocol and interim baseline patient characteristics. BMC Endocr Disord. 2021;21(1):232doi: 10.1186/s12902-021-00888-2.
Gittoes, N., Rejnmark, L., Ing, S. W., Brandi, M. L., Björnsdottir, S., Hahner, S., Hofbauer, L. C., Houillier, P., Khan, A. A., Levine, M. A., Mannstadt, M., Shoback, D. M., Vokes, T. J., Zhang, P., Marelli, C., Germak, J., & Clarke, B. L. (2021). The PARADIGHM (physicians advancing disease knowledge in hypoparathyroidism) registry for patients with chronic hypoparathyroidism: study protocol and interim baseline patient characteristics. BMC endocrine disorders, 21(1), 232. https://doi.org/10.1186/s12902-021-00888-2
Gittoes, Neil, et al. "The PARADIGHM (physicians advancing disease knowledge in hypoparathyroidism) registry for patients with chronic hypoparathyroidism: study protocol and interim baseline patient characteristics." BMC endocrine disorders vol. 21,1 (2021): 232. doi: https://doi.org/10.1186/s12902-021-00888-2
Gittoes N, Rejnmark L, Ing SW, Brandi ML, Björnsdottir S, Hahner S, Hofbauer LC, Houillier P, Khan AA, Levine MA, Mannstadt M, Shoback DM, Vokes TJ, Zhang P, Marelli C, Germak J, Clarke BL. The PARADIGHM (physicians advancing disease knowledge in hypoparathyroidism) registry for patients with chronic hypoparathyroidism: study protocol and interim baseline patient characteristics. BMC Endocr Disord. 2021 Nov 20;21(1):232. doi: 10.1186/s12902-021-00888-2. PMID: 34801015; PMCID: PMC8606089.
Copy Download .nbib Format: NLM
PaTH Forward: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of TransCon PTH in Adult Hypoparathyroidism.

The Journal of clinical endocrinology and metabolism

Khan AA, Rejnmark L, Rubin M, Schwarz P, Vokes T, Clarke B, Ahmed I, Hofbauer L, Marcocci C, Pagotto U, Palermo A, Eriksen E, Brod M, Markova D, Smith A, Pihl S, Mourya S, Karpf DB, Shu AD.
PMID: 34347093
J Clin Endocrinol Metab. 2022 Jan 01;107(1):e372-e385. doi: 10.1210/clinem/dgab577.

CONTEXT: Hypoparathyroidism is characterized by insufficient levels of parathyroid hormone (PTH). TransCon PTH is an investigational long-acting prodrug of PTH(1-34) for the treatment of hypoparathyroidism.OBJECTIVE: This work aimed to investigate the safety, tolerability, and efficacy of daily TransCon PTH...

Cite
Khan AA, Rejnmark L, Rubin M, et al. PaTH Forward: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of TransCon PTH in Adult Hypoparathyroidism. J Clin Endocrinol Metab. 2022;107(1):e372-e385doi: 10.1210/clinem/dgab577.
Khan, A. A., Rejnmark, L., Rubin, M., Schwarz, P., Vokes, T., Clarke, B., Ahmed, I., Hofbauer, L., Marcocci, C., Pagotto, U., Palermo, A., Eriksen, E., Brod, M., Markova, D., Smith, A., Pihl, S., Mourya, S., Karpf, D. B., & Shu, A. D. (2022). PaTH Forward: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of TransCon PTH in Adult Hypoparathyroidism. The Journal of clinical endocrinology and metabolism, 107(1), e372-e385. https://doi.org/10.1210/clinem/dgab577
Khan, Aliya A, et al. "PaTH Forward: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of TransCon PTH in Adult Hypoparathyroidism." The Journal of clinical endocrinology and metabolism vol. 107,1 (2022): e372-e385. doi: https://doi.org/10.1210/clinem/dgab577
Khan AA, Rejnmark L, Rubin M, Schwarz P, Vokes T, Clarke B, Ahmed I, Hofbauer L, Marcocci C, Pagotto U, Palermo A, Eriksen E, Brod M, Markova D, Smith A, Pihl S, Mourya S, Karpf DB, Shu AD. PaTH Forward: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of TransCon PTH in Adult Hypoparathyroidism. J Clin Endocrinol Metab. 2022 Jan 01;107(1):e372-e385. doi: 10.1210/clinem/dgab577. PMID: 34347093.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 197 entries